Breakthrough Nanorod Tech Could Deliver Gene Therapy Directly to Cancer Cells – Technology Networks
Technology Networks |
Breakthrough Nanorod Tech Could Deliver Gene Therapy Directly to Cancer Cells
Technology Networks First, the vector was bound to the ‘enhanced green fluorescent protein’ (EGFP) gene, and then transferred into mammalian cells by the lipid-coated gold nanorods. Exposing cells to near-infrared laser for ten seconds heated up the gold nanorods, turning … |
Technology Networks |
Breakthrough Nanorod Tech Could Deliver Gene Therapy Directly to Cancer Cells
Technology Networks First, the vector was bound to the ‘enhanced green fluorescent protein’ (EGFP) gene, and then transferred into mammalian cells by the lipid-coated gold nanorods. Exposing cells to near-infrared laser for ten seconds heated up the gold nanorods, turning … |
Technology Networks |
Breakthrough Nanorod Tech Could Deliver Gene Therapy Directly to Cancer Cells
Technology Networks First, the vector was bound to the ‘enhanced green fluorescent protein’ (EGFP) gene, and then transferred into mammalian cells by the lipid-coated gold nanorods. Exposing cells to near-infrared laser for ten seconds heated up the gold nanorods, turning … |
Technology Networks |
Breakthrough Nanorod Tech Could Deliver Gene Therapy Directly to Cancer Cells
Technology Networks First, the vector was bound to the ‘enhanced green fluorescent protein’ (EGFP) gene, and then transferred into mammalian cells by the lipid-coated gold nanorods. Exposing cells to near-infrared laser for ten seconds heated up the gold nanorods, turning … |
FierceBiotech |
Neon partners up with CRISPR Therapeutics for IO work
FierceBiotech It’s been a good week for Neon: After posting positive cancer vaccine data a few days ago, the Fierce 15 winner has signed a new R&D pact with gene-editing biotech CRISPR Therapeutics. In a brief update, the pair said that the “research collaboration … |
pharmaphorum |
First gene therapy — ‘a true living drug’ — on the cusp of FDA approval
Washington Post The CAR T-cell treatment, manufactured by the drug company Novartis, initially would be available only for the small number of children and young adults whose leukemia doesn’t respond to standard care. Those patients typically have a grim prognosis … Novartis CAR–T safety in FDA spotlightpharmaphorum |